Last updated: October 29, 2026
FLUARIX and FLUARIX QUADRIVALENT are seasonal influenza vaccines marketed by GSK. Their commercial outlook is driven primarily by annual strain selection, government and institutional procurement, manufacturing capacity, vaccination rates, and competition from Sanofi and CSL Seqirus. Patent protection is less important than for conventional small-molecule drugs because annual regulatory updates, biologic manufacturing know-how, supply reliability, and public-health purchasing contracts determine market access.
GSK does not separately disclose global revenue for FLUARIX or FLUARIX QUADRIVALENT. The products are reported within the company’s broader vaccines business, which is increasingly concentrated in higher-value products such as Shingrix and Arexvy. FLUARIX remains a recurring seasonal product, but its financial contribution is smaller and less strategically important than GSK’s leading vaccines.
What are FLUARIX and FLUARIX QUADRIVALENT?
FLUARIX is an inactivated influenza vaccine administered by intramuscular injection. FLUARIX QUADRIVALENT was designed to protect against four influenza virus strains: two influenza A strains and two influenza B lineage strains.
| Product |
Active technology |
Historical strain coverage |
Manufacturer |
Primary use |
| FLUARIX |
Inactivated influenza vaccine |
Trivalent |
GSK |
Seasonal influenza prevention |
| FLUARIX QUADRIVALENT |
Inactivated influenza vaccine |
Quadrivalent |
GSK |
Seasonal influenza prevention |
| FLUARIX 2024-2025 formulation |
Inactivated influenza vaccine |
Trivalent |
GSK |
Current-season influenza prevention |
The United States moved back to trivalent influenza vaccines for the 2024-2025 season after the World Health Organization determined that the influenza B/Yamagata lineage had not been detected in global surveillance for several years. The FDA directed manufacturers to remove the B/Yamagata component from U.S. seasonal influenza vaccines (FDA, 2024a).
What is the FDA regulatory status of FLUARIX?
FLUARIX is licensed in the United States under a biologics license application rather than an ordinary new drug application. The FDA approved FLUARIX QUADRIVALENT in 2012. The product has received subsequent annual strain-composition updates.
FDA regulatory milestones
| Event |
Date |
Significance |
| FLUARIX QUADRIVALENT FDA approval |
2012 |
Initial U.S. approval for four-strain coverage |
| Annual strain updates |
Recurring |
Required to match seasonal influenza recommendations |
| FDA adoption of trivalent 2024-2025 composition |
2024 |
Removal of influenza B/Yamagata component |
| 2024-2025 U.S. season |
2024-2025 |
GSK marketed a trivalent FLUARIX formulation |
Annual strain changes are generally handled through regulatory supplements and manufacturing controls rather than a completely new biologic license. The product’s regulatory value therefore comes from the approved platform, manufacturing process, safety database, and ability to deliver updated seasonal lots on time.
When does FLUARIX lose exclusivity?
FLUARIX does not have a single practical “loss of exclusivity” date comparable to a small-molecule drug with one primary composition-of-matter patent.
The product is subject to several overlapping protection mechanisms:
- Biologics license approval
- Manufacturing process controls
- Annual strain-selection and supplement procedures
- Facility qualification
- Product-specific clinical and safety data
- Trademarks and brand recognition
- Government and institutional procurement relationships
- Cold-chain and seasonal production capacity
The original patents associated with influenza vaccine compositions or manufacturing processes are unlikely to determine current market access. Any patent term associated with the original FLUARIX QUADRIVALENT approval would have begun more than a decade ago, while seasonal formulations and manufacturing methods may have separate patent positions. Publicly available information does not establish a single unexpired patent that independently blocks all competing influenza vaccines.
Is FLUARIX listed in the Orange Book?
No conventional Orange Book exclusivity analysis applies. The FDA Orange Book primarily covers approved small-molecule drug products and certain related products. FLUARIX is a biologic licensed under the Public Health Service Act. Its regulatory record is maintained through FDA biologics systems rather than an Orange Book patent-listing strategy.
FLUARIX is also not typically analyzed through the Purple Book biosimilar framework. A seasonal influenza vaccine is not a biosimilar reference product in the same sense as a monoclonal antibody or recombinant protein.
How strong is the FLUARIX patent estate?
The patent estate is commercially moderate but strategically secondary to manufacturing and regulatory execution.
| Protection category |
Relevance to FLUARIX |
| Composition-of-matter patents |
Limited value for an annually updated, multistrain vaccine |
| Formulation patents |
Potentially relevant for stabilizers, adjuvants, dose presentation, and storage |
| Method-of-use patents |
Narrow commercial effect because seasonal influenza prevention is established |
| Manufacturing patents |
High practical relevance if they cover yield, purification, inactivation, or fill-finish |
| Trade secrets |
High relevance for process parameters and quality control |
| Trademarks |
Important for procurement and physician recognition |
| Regulatory know-how |
High relevance because seasonal supply must meet fixed delivery windows |
What formulations are protected by FLUARIX patents?
Publicly available product information identifies FLUARIX as an inactivated influenza vaccine. It does not establish a current, broad formulation patent that prevents competing manufacturers from selling an inactivated influenza vaccine.
Potentially protectable technical areas include:
- Virus propagation and harvest
- Purification and concentration
- Chemical inactivation
- Antigen standardization
- Stabilization during storage
- Prefilled syringe or vial presentation
- Manufacturing yield and lot consistency
- Strain-specific process adaptations
These protections tend to be narrow and process-dependent. They may raise manufacturing costs for a challenger without preventing all competing vaccines.
Which companies compete with FLUARIX?
The U.S. influenza vaccine market has three major commercial suppliers: Sanofi, CSL Seqirus, and GSK.
| Company |
Major influenza brands |
Competitive position |
| Sanofi |
Fluzone, Fluzone High-Dose, Fluzone Quadrivalent |
Broad U.S. retail, institutional, and senior market reach |
| CSL Seqirus |
Fluad, Afluria |
Strong presence in adjuvanted, cell-based, and egg-based vaccines |
| GSK |
FLUARIX, FLUARIX QUADRIVALENT |
Established branded franchise with institutional and retail distribution |
| AstraZeneca |
FluMist |
Intranasal live attenuated vaccine; distinct delivery proposition |
GSK’s main competitive disadvantage is that influenza vaccination is a procurement-driven market with limited brand loyalty. Buyers often prioritize price, delivery reliability, age indication, presentation, and reimbursement over brand differentiation.
FLUARIX competes directly with standard-dose inactivated vaccines. It is less differentiated against high-dose or adjuvanted vaccines designed for older adults, and it does not have the same delivery format as FluMist.
What drives the FLUARIX market?
Seasonal demand and vaccination rates
Demand is highly seasonal and depends on:
- Influenza severity
- Public concern about respiratory illness
- Physician recommendations
- Employer and school vaccination programs
- Medicare and other reimbursement policies
- Public-health campaigns
- Vaccine effectiveness perceptions
- Timing of strain recommendations
- Production and delivery schedules
A late or mild influenza season can reduce demand even when vaccine supply is adequate. A severe season can increase demand but may arrive too late to fully recover lost vaccination opportunities.
Government procurement
Government purchases and public programs create a significant portion of influenza vaccine demand. In the United States, federal, state, local, and institutional buyers purchase vaccines through contracts and tenders. Price competition is intense, and supply reliability can be as important as unit price.
The Centers for Disease Control and Prevention recommends annual influenza vaccination for everyone six months and older, subject to product-specific age and medical considerations (CDC, 2024). That broad recommendation supports a large addressable market but does not guarantee a particular manufacturer’s volume.
Product mix
FLUARIX’s standard-dose positioning limits pricing power. Higher-priced influenza products may have stronger economics when they target older adults, use adjuvants, or rely on cell-based or recombinant production.
GSK’s influenza strategy is therefore affected by product mix across the entire vaccine portfolio. The company’s growth capital and commercial attention have shifted toward vaccines with stronger differentiation and higher revenue per dose.
What is the financial trajectory for FLUARIX?
GSK does not publish a separate FLUARIX or FLUARIX QUADRIVALENT revenue line in its annual reports. The company reports influenza products within broader vaccines revenue or product categories, preventing a reliable public calculation of brand-specific sales, gross margin, or operating profit.
The financial trajectory can be summarized as follows:
| Period |
Financial interpretation |
| Pre-pandemic period |
Recurring seasonal revenue with established distribution |
| 2020-2021 |
Disrupted vaccination behavior and altered healthcare utilization |
| 2022-2023 |
Recovery in routine immunization and respiratory vaccine demand |
| 2024 onward |
Trivalent transition in the U.S.; continued price and tender pressure |
| Long term |
Stable seasonal cash generation but limited growth relative to GSK’s newer vaccines |
GSK’s vaccines business has grown substantially in strategic importance because of Shingrix, Arexvy, meningitis vaccines, and other products. FLUARIX is likely to remain a recurring revenue contributor, but it is not one of the principal drivers of GSK’s vaccine valuation.
The product’s economics are constrained by:
- Annual production deadlines
- Inventory risk after the influenza season
- High compliance and quality-control costs
- Procurement discounts
- Multiple approved competitors
- Limited ability to raise prices
- Changing strain compositions
- Demand volatility
Are there licensing deals involving FLUARIX?
No major current licensing transaction publicly defines the commercial value of FLUARIX. GSK’s influenza franchise is associated with its internal vaccine operations and the company’s historical ownership of vaccine manufacturing assets, including the former ID Biomedical business.
There is no widely reported licensing deal that gives a third party control over the core FLUARIX brand, a platform patent, or exclusive U.S. commercialization rights. Commercial distribution arrangements may exist by country or channel, but they do not appear to be the central determinant of the product’s public financial profile.
What patent litigation affects FLUARIX?
No major current U.S. Paragraph IV case is publicly identified as a central threat to FLUARIX. Paragraph IV litigation is designed for abbreviated new drug applications and Orange Book-listed patents. FLUARIX is a biologic vaccine, and competing products generally enter through their own biologics licensing pathways rather than by relying on a direct generic substitution mechanism.
Potential disputes could involve:
- Manufacturing methods
- Strain-specific compositions
- Delivery devices
- Labeling
- Trade secrets
- Contract manufacturing
- Regulatory exclusivity
- Procurement practices
These risks are materially different from patent litigation involving blockbuster small-molecule drugs.
What generic and biosimilar entry risks exist?
Traditional generic substitution risk is low because vaccines are not interchangeable with ordinary small-molecule generics. Biosimilar risk is also limited in the formal statutory sense because influenza vaccines are not typical biosimilar reference products.
Competitive entry remains high, however. Sanofi, CSL Seqirus, AstraZeneca, and other manufacturers can compete through independently developed vaccines. The principal threat is therefore product substitution, not patent-enabled generic launch.
A new entrant would need to establish:
- A validated manufacturing process.
- FDA biologics licensure.
- Seasonal strain updates.
- Commercial-scale production.
- Quality and lot-release capability.
- Distribution before the vaccination season.
- Procurement access and reimbursement coverage.
These requirements create meaningful barriers, but they do not provide FLUARIX with durable market exclusivity.
What generic launch scenarios exist for FLUARIX?
A conventional AB-rated generic launch is not the principal scenario. More realistic competitive scenarios are:
| Scenario |
Commercial effect on GSK |
| New standard-dose vaccine supplier |
Price pressure and tender share loss |
| Expanded Sanofi or Seqirus capacity |
Reduced institutional volume |
| Growth of cell-based or recombinant vaccines |
Segment shift away from egg-based products |
| Increased FluMist use |
Substitution in pediatric and needle-averse populations |
| Higher adoption of adjuvanted or high-dose products |
Reduced relevance of standard-dose FLUARIX |
| Supply disruption at a competitor |
Temporary volume opportunity for GSK |
| Strong influenza season |
Higher market demand, subject to available inventory |
How does FLUARIX compare with Fluzone and Fluad?
| Factor |
FLUARIX |
Fluzone |
Fluad |
| Company |
GSK |
Sanofi |
CSL Seqirus |
| Core technology |
Inactivated vaccine |
Inactivated vaccine |
Adjuvanted inactivated vaccine |
| Main differentiation |
Established brand and supply |
Broad portfolio and high-dose franchise |
Older-adult positioning |
| Pricing power |
Moderate to low |
Higher for premium presentations |
Higher than standard-dose products |
| Main risk |
Commodity competition |
Portfolio complexity and supply execution |
Narrower age-focused positioning |
| Patent importance |
Secondary |
Secondary |
Secondary |
FLUARIX is strongest when GSK can provide reliable seasonal supply at competitive prices. Fluzone has greater commercial breadth, while Fluad has stronger product differentiation for older adults.
What is the geographic coverage of FLUARIX?
FLUARIX has been commercialized across multiple markets, subject to local regulatory approvals and seasonal vaccine policies. Geographic performance depends on:
- National vaccination recommendations
- Government tenders
- Local manufacturing or import requirements
- Reimbursement
- Strain composition
- Distribution infrastructure
- Local influenza epidemiology
The United States remains commercially important, but Europe and other developed markets also contribute to recurring seasonal demand. Emerging-market opportunities are constrained by lower vaccination rates, public-health budgets, and cold-chain requirements.
What manufacturing and intellectual-property barriers protect FLUARIX?
The largest barriers are operational rather than patent-based. A manufacturer must reserve capacity months before the influenza season, produce multiple strains, satisfy stringent release testing, and deliver large volumes within a narrow period.
Manufacturing barriers include:
- Egg or cell substrate availability
- Strain propagation performance
- Yield variability
- Contamination control
- Inactivation and purification
- Antigen potency testing
- Fill-finish capacity
- Cold-chain distribution
- Lot-release timing
These barriers protect incumbent suppliers from rapid entry. They do not prevent well-capitalized vaccine companies with existing influenza platforms from competing.
Key Takeaways
- FLUARIX and FLUARIX QUADRIVALENT are GSK seasonal inactivated influenza vaccines.
- The U.S. market moved back to trivalent formulations for the 2024-2025 season after removal of influenza B/Yamagata.
- GSK does not separately disclose FLUARIX revenue, margins, or operating profit.
- The franchise produces recurring seasonal revenue but is less strategically important than Shingrix and Arexvy.
- No single patent expiration date defines FLUARIX market entry.
- Orange Book and conventional Paragraph IV analysis have limited application.
- Generic and biosimilar substitution risk is low in the formal sense, but competitive vaccine entry remains substantial.
- Sanofi and CSL Seqirus are the principal commercial competitors.
- Manufacturing capacity, regulatory execution, procurement access, and delivery timing are stronger defenses than composition patents.
- FLUARIX’s long-term financial profile is stable but low-growth, with pricing pressure and product-mix risk.
FAQs
Does FLUARIX have a biosimilar competitor?
No conventional biosimilar competitor has replaced FLUARIX. Competing influenza vaccines are independently developed biologics with their own regulatory approvals.
Is FLUARIX QUADRIVALENT still used in the United States?
The United States transitioned to trivalent seasonal influenza vaccines for the 2024-2025 season. The regulatory status of earlier quadrivalent presentations does not determine the formulation selected for each current season.
Is FLUARIX a high-dose influenza vaccine?
No. FLUARIX is generally positioned as a standard-dose inactivated influenza vaccine. High-dose products, such as Fluzone High-Dose, target a different commercial segment.
Can a pharmacy automatically substitute another vaccine for FLUARIX?
Substitution depends on state law, payer rules, product labeling, age eligibility, and pharmacy policy. Influenza vaccines are competitive products, but they are not ordinary AB-rated generic substitutions.
What is the largest commercial risk to FLUARIX?
The largest risk is loss of seasonal procurement volume to competing vaccines, particularly if Sanofi or CSL Seqirus offers stronger pricing, differentiated products, or more reliable supply.
References
-
Centers for Disease Control and Prevention. (2024). Who should and should not get a flu vaccine. https://www.cdc.gov/flu/vaccines/index.html
-
GSK plc. (2024). Annual report 2023. https://www.gsk.com/en-gb/investors/annual-report/
-
GSK plc. (2025). Annual report 2024. https://www.gsk.com/en-gb/investors/annual-report/
-
U.S. Food and Drug Administration. (2024a). 2024-2025 formula for influenza vaccines in the United States. https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-availability
-
U.S. Food and Drug Administration. (2024b). FLUARIX QUADRIVALENT prescribing information. https://www.fda.gov/vaccines-blood-biologics/vaccines/fluarix-quadrivalent
-
World Health Organization. (2024). Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations-candidate-vaccine-viruses
